Questions and Answers

DELs are significant in drug discovery because they provide an efficient way to screen very large compound libraries for new druglike molecules.

DEL screening works by identifying molecules in the DEL that binds to a drug target. Vipergen uses a proprietary process, Binder Trap Enrichment, to do the binding in solution and avoid matrix effects that are often seen when solid phase binding is employed. In the newest version, the binding is performed in the inside of a living cell. The molecules binding to the target are identified by Next Generation Sequencing.

Yes, Vipergen has successfully identified molecular glue compounds from DELs.

Before screening, Vipergen performs a feasibility study to ensure that the target is expressed appropriately. In our experience, most cytoplasmic proteins, including membrane proteins accessible from the cytoplasm, can be screened in cells.

Most cytoplasmic proteins, including membrane proteins accessible from the cytoplasm, can be screened in cells. Vipergen has experience with several protein classes, including enzymes, protein-protein interaction targets, and many more.

Yes, Vipergen has successfully screened heteromultimers up to a size of 2.6 MDa in cells. In principle, there is no theoretical limit to the size or complexity of heteromultimer that can be screened in cells.